About Lundbeck
Lundbeck is a publicly listed company based in Copenhagen (Denmark) founded in 1915. Drugs for CNS disorders are developed and advanced. The company has 5,710 employees. Lundbeck has completed 8 acquisitions, including Abide Therapeutics, Alder and Alder Biopharmaceuticals. Its website lundbeck.com draws about 138 thousand monthly visits. Its Indian entity Lundbeck India Private Limited reported revenue of ₹1.23 Cr. Its focus areas include Life Sciences, Neurology, Drugs and Diversified.
Company details
The company was founded in 1915 in Copenhagen, Denmark, and operates within the pharmaceutical sector. Emphasis is placed on developing treatments for central nervous system disorders. The lead product, Eptinezumab, is a monoclonal antibody used for migraine and cluster headache management. A research pipeline is pursued for depression, schizophrenia, Alzheimers disease, Parkinsons disease, and insomnia, with operations centered in Europe and global outreach.
- Headquarters Copenhagen, Denmark
- Employees 5,710
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website lundbeck.com/global
- Social LinkedIn X
- Legal Name H. Lundbeck A/S Class A
- Indian entity revenue₹1.23 Cr
FY 2023 · -91% YoY
- Indian entity net profit₹48.4 Lakh
FY 2023 · 40% margin
- Indian entity EBITDA₹52.7 Lakh
FY 2023 · 43% margin
- Latest Funding Round$338.46K (USD), Grant
Mar 2019
- InvestorsEuropean Union
& 1 more
- Employee Count5,710
- Investments & AcquisitionsAbide Therapeutics
& 7 more
Associated legal entities of Lundbeck
Lundbeck operates through Lundbeck India Private Limited (under liquidation). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2023) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Lundbeck India Private Limited CIN U24231KA2002PTC029998 | Under Liquidation | 16 Jan 2002 | Bangalore, Karnataka | ₹1.2 Cr | 2 | 2 | View details |
Funding Insights of Lundbeck
- Total Rounds 8
- Last Round Grant — $338,463
- First Round $574,355
(Jun 2011)
- Investors Count 2
All 8 funding rounds of Lundbeck with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2019 | $338,463 | Grant | – | – | |
| Jan 2017 | $51,314 | Grant | – | – | |
| Dec 2016 | $309,256 | Grant | – | – | |
| May 2016 | $332,475 | Grant | – | – | |
| Jan 2016 | $81,450 | Grant | – | – | |
| Mar 2015 | $323,717 | Grant | – | – | |
| Jun 2011 | $574,355 | Post-IPO | – | – | |
| Jun 2011 | $174,046 | Post-IPO | – | – |
2 investors in total: 2 institutional.
Investors in Lundbeck
Lundbeck has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union and IFU.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investment firm | 1967 | ifu.dk | Copenhagen, Denmark | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Lundbeck
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Lundbeck India Private Limited (Lundbeck)
Lundbeck India Private Limited is the primary company behind Lundbeck. The board of Lundbeck India Private Limited currently have 2 directors; the longest-serving is Morten Bryde Hansen, appointed in 2004. 10 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Morten Bryde Hansen DIN 01410904 | Director | 05 Jan 2004 | 22 yrs 10 mo | Lundbeck India Private Limited |
| Riyan Ahmed Khan DIN 10191766 | Director | 11 Sep 2023 | 3 yrs 2 mo | Lundbeck India Private Limited |
People of Lundbeck
587 people are tracked at Lundbeck (246 in leadership, 11 in board & advisors, 330 in team); the tracked headcount is 5,710.
| Name | Role | Group |
|---|---|---|
Anders Gotzsche | CFO | Leadership |
Alexandria Bond | Senior Director Of US Legal Affairs And Assistant General Counsel | Leadership |
Tina Kirstein Thygesen | Director | Leadership |
Mette Maigaard | Head Of Agile Center | Leadership |
Jay Mashburn | Director, Regulatory Affairs Alliance And Commercialization | Leadership |
Neha Kapur | Associate Medical Director - Neurology | Leadership |
John Schillo | Payer Account Director, Government | Leadership |
Yifan Zhang | Managing Director / General Manager | Leadership |
Liv Trolle | Director, Global Customer Engagement Excellence | Leadership |
Dierk Schoch | Senior Vice President Europe | Leadership |
Bodil Klink Larsen | Senior People & Organization Partner, Commercial Operations Europe | Leadership |
Seema Soni-Brahmbhatt | Medical Director Neurology | Leadership |
Mads Bjærge | Head Of IT Quality & Compliance | Leadership |
Heather Strawn | Vice President | Leadership |
Nancy Aiello | Senior Director, US Regulatory Strategy | Leadership |
Rebekah Snyder Logan | Head Of US Regulatory Affairs | Leadership |
Sherif Esmail | Marketing Director | Leadership |
Kamilla Buchberg Petersen | Senior Director | Leadership |
Debra Eisenberg | Director HEOR - Vyepti | Leadership |
Joe Kane | Brand Lead, Director | Leadership |
567 more people are available in the full profile.
Complete people profiles for Lundbeck
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Lundbeck
Lundbeck is a publicly listed company on the OMXCOP with ticker symbol HLUN_A in Denmark, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 Jun 2002
- Listed onNASDAQ OMX: LUN
- Listed entityH. Lundbeck A/S Class A
- Exchange sectorHealth technology
- ISINDK0061804697
- Share price44.55 DKK (+0.68% on the day) · 2026-10-14
- Market capitalisation46,020,252,193.00 DKK
- Price to earnings11.4
- EPS (diluted, trailing year)3.91 DKK
- Dividend yield2.6%
- Volume (last session)19,905
Financials of Lundbeck
Figures of Lundbeck India Private Limited, the primary company behind Lundbeck, for FY 2023. Revenue was ₹1.23 Cr (-91% year on year). Net profit was ₹48.4 Lakh (40% margin). EBITDA was ₹52.7 Lakh (43% margin). Revenue has grown at a compounded annual rate of -62% over three years and -38% over five years.
- ₹1.23 CrRevenue · FY 2023 · -91% YoY
- ₹48.4 LakhNet profit · 40% margin
- ₹52.7 LakhEBITDA · 43% margin
- ₹5.00 CrPaid-up capital
- 2Employees (provident fund records)
- -62%Revenue CAGR, 3 years
- -38%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 24.35B DKK | 3.19B DKK | 8.66B DKK |
| 2024 | 22.06B DKK | 3.14B DKK | 6.17B DKK |
| 2023 | 19.91B DKK | 2.29B DKK | 5.21B DKK |
| 2022 | 18.25B DKK | 1.92B DKK | 4.66B DKK |
| 2021 | 16.30B DKK | 1.32B DKK | 3.72B DKK |
Balance sheet, profit and loss, cash flow and ratios of Lundbeck India Private Limited are on its company page.
Detailed financial statements for Lundbeck
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lundbeck
Lundbeck has strategically engaged in corporate development activities, having acquired 8 companies. Notable acquisitions include Abide Therapeutics, Alder and Alder Biopharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutic solutions for rare neurological diseases are developed. | longboardpharma.com | San Diego, United States | 2020 | Oct 2024 | $2.6B | |
Furniture is retailed by Alder in Delhi, India. | alder.in | Delhi, India | 2004 | Sep 2019 | $1.95B | |
Humanized monoclonal antibodies are developed for migraine and inflammatory diseases. | alderbio.com | Bothell, United States | 2004 | Sep 2019 | $1.95B | |
Serine hydrolase inhibitors are developed for pain management. | abidetx.com | San Diego, United States | 2011 | May 2019 | $250M | |
Parkinson's drugs targeting mGluR3 and mGluR4 receptors are developed. | prextontherapeutics.com | 2012 | Mar 2018 | $123.45M | ||
A drug for symptomatic neurogenic orthostatic hypotension was developed. | chelsearx.com | Charlotte, United States | 2004 | May 2014 | $658M | |
Manufacturer of prescription drugs | ovationpharma.com | Deerfield, United States | 2000 | Feb 2009 | $900M | |
Small molecule therapeutics for behavioural disorders were developed. | saegispharma.com | Half Moon Bay, United States | 1999 | Jun 2006 | $820M |
Complete acquisition details for Lundbeck
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Lundbeck
12 dated milestones of Lundbeck across 109 years, from founding to its latest funding, stage changes and deals.
- Founded Lundbeck is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Saegis Pharma.
- Acquisition Acquires Ovation Pharmaceuticals.
- Funding First funding round of $574K.
- Acquisition Acquires Chelsea Therapeutics.
- Acquisition Acquires Prexton Therapeutics.
- Funding Latest funding round, Grant, of $338K.
- Acquisition Acquires Abide Therapeutics.
- Acquisition Acquires Alder.
- Acquisition Acquires Alder Biopharmaceuticals.
- Acquisition Acquires Longboard Pharmaceutical.
Web traffic of Lundbeck
The website of Lundbeck (lundbeck.com) receives about 137.6K visits a month and ranks #280,857 among all websites worldwide, #9,637 in Biotechnology and Pharmaceuticals.
- Monthly visits137.6K
▼ 13.2% vs previous month
- Unique visitors70.9K
per month
- Global rank#280,857
among all websites
- Category rank#9,637
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit1.8
- Average visit38 sec
- DevicesDesktop 33% · Mobile 67%
Websites whose visitors overlap most with Lundbeck. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| leo-pharma.com | 100% | 90.7K | #474,135 | View details | |
| novartis.com | 98% | 948.8K | #58,822 | View details | |
| bavarian-nordic.com | 92% | 31.7K | #762,962 | View details | |
| pfizer.com | 88% | 1.9M | #24,984 | View details | |
| merck.com | 87% | 656.8K | #78,842 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Lundbeck
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lundbeck
Complete news archive for Lundbeck
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lundbeck
Lundbeck was founded in 1915 and raised its 1st funding round 96 years after it was founded.
Lundbeck is headquartered in Copenhagen, Denmark.
Lundbeck has 5,710 employees.
The primary company behind Lundbeck, Lundbeck India Private Limited, reported revenue of ₹1.23 Cr for FY 2023, down 91% year on year.
The company was founded in 1915 in Copenhagen, Denmark, and operates within the pharmaceutical sector. Emphasis is placed on developing treatments for central nervous system disorders. The lead product, Eptinezumab, is a monoclonal antibody used for migraine and cluster headache management. A research pipeline is pursued for depression, schizophrenia, Alzheimers disease, Parkinsons disease, and insomnia, with operations centered in Europe and global outreach.
Yes, Lundbeck is publicly traded on OMXCOP under the ticker symbol HLUN_A.
Lundbeck has made 8 acquisitions, including Abide Therapeutics, Alder, and Alder Biopharmaceuticals.
Lundbeck has 2 investors. Key investors include European Union, and IFU.
Lundbeck operates through Lundbeck India Private Limited.
The legal entities of Lundbeck currently have 2 directors, including Morten Bryde Hansen, Riyan Ahmed Khan.
The website of Lundbeck receives about 138 thousand visits a month and ranks #280,857 among all websites worldwide.